1. ENTPD1 (CD39) and NT5E (CD73) expression in human glioblastoma: an in silico analysis.
- Author
-
Braganhol E, de Andrade GPB, Santos GT, and Stefani MA
- Subjects
- Humans, GPI-Linked Proteins metabolism, GPI-Linked Proteins genetics, GPI-Linked Proteins biosynthesis, Male, Female, Middle Aged, Gene Expression Regulation, Neoplastic, Prognosis, Glioblastoma metabolism, Glioblastoma genetics, 5'-Nucleotidase metabolism, 5'-Nucleotidase genetics, 5'-Nucleotidase biosynthesis, Brain Neoplasms metabolism, Brain Neoplasms genetics, Apyrase metabolism, Apyrase genetics, Apyrase biosynthesis, Computer Simulation
- Abstract
Glioblastoma (GB) is the most common primary brain tumor in adults and carries a dismal prognosis, despite the best available treatment. The 2021 WHO Classification of CNS tumors incorporated molecular profiling to better define the characteristics and prognosis of tumor types and subtypes. These recent advances in diagnosis have not yet resulted in breakthrough therapies capable of shifting the treatment paradigm. NT5E/CD73 is a cell surface enzyme that participates in a complex purinergic pathway in synergy with ENTPD1/CD39 producing extracellular adenosine (ADO) from ATP. ADO promotes tumor progression by inducing immunosuppression, stimulating adhesion, invasion, and angiogenesis. In this study, we performed an in silico analysis of 156 human glioblastoma samples in an unexplored public database to investigate the transcriptional levels of NT5E and ENTPD1. The analysis revealed a significant increase in transcription levels of the genes under study in GB samples versus non-tumor brain tissue samples, in concordance with previous studies. High transcriptional levels of NT5E or ENTPD1 were independently related to a decrease in overall survival (p = 5.4e-04; 1.1e-05), irrespective of the IDH mutation status. NT5E transcriptional levels were significantly higher in GB IDH wild-type patients compared to GB IDH-mutant; however, ENTPD1 levels showed no significant difference, p ≤ 0.001. This in silico study indicates the need for a deeper understanding of the purinergic pathway relation to GB development, also inspiring future population studies that could explore ENTPD1 and NT5E not only as prognostic markers but also as potential therapeutic targets., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF